SK6172000A3 - Use of macrolides for the treatment of cancer and macular degeneration - Google Patents

Use of macrolides for the treatment of cancer and macular degeneration Download PDF

Info

Publication number
SK6172000A3
SK6172000A3 SK617-2000A SK6172000A SK6172000A3 SK 6172000 A3 SK6172000 A3 SK 6172000A3 SK 6172000 A SK6172000 A SK 6172000A SK 6172000 A3 SK6172000 A3 SK 6172000A3
Authority
SK
Slovakia
Prior art keywords
substituted
heteroaryl
defined above
alkyl
group
Prior art date
Application number
SK617-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Yat Sun Or
Jacob J Plattner
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of SK6172000A3 publication Critical patent/SK6172000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
SK617-2000A 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration SK6172000A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96147397A 1997-10-31 1997-10-31
PCT/US1998/023043 WO1999022722A2 (fr) 1997-10-31 1998-10-30 Utilisation de macrolides pour le traitement du cancer et de la degenerescence maculaire

Publications (1)

Publication Number Publication Date
SK6172000A3 true SK6172000A3 (en) 2001-03-12

Family

ID=25504514

Family Applications (1)

Application Number Title Priority Date Filing Date
SK617-2000A SK6172000A3 (en) 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration

Country Status (17)

Country Link
EP (1) EP1027060A2 (fr)
JP (1) JP2001521891A (fr)
KR (1) KR20010031577A (fr)
CN (1) CN1278178A (fr)
AR (1) AR043071A1 (fr)
AU (1) AU1206799A (fr)
BG (1) BG104436A (fr)
BR (1) BR9813318A (fr)
CA (1) CA2307850A1 (fr)
HU (1) HUP0100012A3 (fr)
IL (1) IL135518A0 (fr)
NO (1) NO20002189L (fr)
PL (1) PL340604A1 (fr)
SK (1) SK6172000A3 (fr)
TR (1) TR200001147T2 (fr)
WO (1) WO1999022722A2 (fr)
ZA (1) ZA989885B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4858801A (en) 2000-04-13 2001-10-30 Biotica Tech Ltd Hybrid glycosylated products and their production and use
DK1539157T3 (da) 2002-09-18 2013-10-07 Univ Pennsylvania Fremgangsmåde til hæmning af choroidal neovaskularisering
TW200420573A (en) 2002-09-26 2004-10-16 Rib X Pharmaceuticals Inc Bifunctional heterocyclic compounds and methods of making and using same
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7943800B2 (en) 2003-03-28 2011-05-17 Sloan-Kettering Institute For Cancer Research Migrastatin analogs and uses thereof
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
KR20060085246A (ko) 2003-09-18 2006-07-26 마커사이트, 인코포레이티드 경공막 전달
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
EP1723159B1 (fr) * 2004-02-27 2019-06-12 Melinta Therapeutics, Inc. Composes macrocycliques et leurs procedes de fabrication et d'utilisation
CN108101948A (zh) * 2004-02-27 2018-06-01 瑞伯-X医药品有限公司 大环化合物以及其制作和使用方法
JP5149001B2 (ja) 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
US8188141B2 (en) 2004-09-23 2012-05-29 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
EP1904056B1 (fr) 2005-07-18 2009-04-29 Minu, L.L.C. Utilisation d'un macrolide pour restaurer la sensation cornéenne
EP1934237A2 (fr) 2005-08-24 2008-06-25 Rib-X Pharmaceuticals, Inc. Triazoles et procedes de production et d'utilisation de ces composes
EP3290427A1 (fr) 2005-08-24 2018-03-07 Melinta Therapeutics, Inc. Systèmes à trampoline et procédés de fabrication et d'utilisation de ceux-ci
KR20140093764A (ko) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
CN106317146B (zh) * 2015-06-18 2019-06-21 沈阳药科大学 双环克拉霉素衍生物及其作为肿瘤细胞增值抑制剂的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6461090A (en) * 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity

Also Published As

Publication number Publication date
CA2307850A1 (fr) 1999-05-14
AU1206799A (en) 1999-05-24
ZA989885B (en) 1999-05-05
KR20010031577A (ko) 2001-04-16
AR043071A1 (es) 2005-07-20
PL340604A1 (en) 2001-02-12
NO20002189D0 (no) 2000-04-27
HUP0100012A3 (en) 2003-07-28
BR9813318A (pt) 2000-08-22
TR200001147T2 (tr) 2000-08-21
EP1027060A2 (fr) 2000-08-16
IL135518A0 (en) 2001-05-20
WO1999022722A2 (fr) 1999-05-14
JP2001521891A (ja) 2001-11-13
CN1278178A (zh) 2000-12-27
BG104436A (en) 2000-12-29
WO1999022722A3 (fr) 1999-08-05
NO20002189L (no) 2000-06-28
HUP0100012A2 (hu) 2001-05-28

Similar Documents

Publication Publication Date Title
SK6172000A3 (en) Use of macrolides for the treatment of cancer and macular degeneration
AU2014203882B2 (en) Methods for reducing cellular proliferation and treating certain diseases
EP0929563B1 (fr) Cetolides substitues en 6-o possedant une activite antibacterienne
JP2662094B2 (ja) ４″−デオキシエリスロマイシン誘導体
EP1928470A2 (fr) Modulateurs du facteur 1 induit par hypoxie et utilisations associees dans le traitement de troubles oculaires
CA2876074A1 (fr) Derives de seconde generation n-substitues de l'amphotericine b antibiotique antifongique et leurs procedes de preparation et d'utilisation
JP2836964B2 (ja) １６員環マクロライド系抗生物質の誘導体
KR20140139083A (ko) 마크롤라이드계 항생제를 투여하기 위한 비경구 제제
JP2023109937A (ja) ３－置換１，２，４－オキサジアゾールの結晶形態
EP1025114B1 (fr) Derives d'erythromycine cetolides, modifies en n-3' et substitues en o-6, possedant une activite antibacterienne
CA2367319A1 (fr) Derives d'erythromycine
JPH08508038A (ja) １６員環マクロライド系抗生物質のアミド誘導体
US20020019355A1 (en) Anti-infective agents useful against multidrug-resistant strains of bacteria
JP2003507487A (ja) 抗菌活性を有する９ａ−アザライド類
EP1373289A1 (fr) Macrolide 14-elements- 9-amino derive de la leucomycine
CZ20001524A3 (cs) Farmaceutický přípravek pro léčení nádorů a makulární degenerace
WO2013132014A1 (fr) Dérivés semi-synthétiques de nystatine a1
EP1259923B1 (fr) Agents anti-infectieux utiles contre des souches de bacteries resistant a l'action de plusieurs medicaments
KR20200014880A (ko) 테세탁셀 및 카페시타빈에 대한 투약 일정
US6716820B1 (en) 6-O-substituted bicyclic macrolides
JPH06507407A (ja) エリスロマイシン誘導体
JP2020509086A (ja) トリアゾール含有マクロライド及びその眼科的使用
NZ500531A (en) Multicyclic erythromycin derivatives having antibacterial activity
JP2020511445A (ja) ドライアイ疾患を治療するための組成物および方法
MXPA00005405A (en) 6-o-alkyl erythromycin b oxime